BioLineRx Ltd. (BLRX)
BioLineRx Ltd. reported revenue of 304K USD for the quarter ending 30 June 2025.
Every figure below is the company's own, as filed. Nothing is estimated and
nothing is smoothed — a period the filing does not support is left blank rather than
filled in.
Quarters are the company's own, counted from its financial
year ending 12-31.
Amounts in USD.
The same series drawn ›
As last reported
The newest period the filing supports for each figure, in USD.
| Figure | Period | Amount | Year on year |
|---|
| Revenue |
Q2 '25 · ending 30 June 2025 |
304K |
— |
| Gross Profit |
Q2 '25 · ending 30 June 2025 |
232K |
— |
| Operating Income |
Q2 '25 · ending 30 June 2025 |
-2.3M |
— |
| Net Income |
Q2 '25 · ending 30 June 2025 |
-3.9M |
— |
| Cost of Revenue |
Q2 '25 · ending 30 June 2025 |
72K |
— |
| Shares Outstanding |
Q2 '25 · ending 30 June 2025 |
2.4B |
+254.1% |
| EPS |
2025 · ending 31 December 2025 |
0.00 |
— |
Revenue and profit by financial year
As filed, in USD. A year the filing does not support is not listed.
| Year | Ending |
Revenue | Operating Income | Net Income | Free Cash Flow |
|---|
| 2025 | 2025-12-31 |
1.2M | -10.3M | -2M | -8.1M |
|---|
| 2024 | 2024-12-31 |
28.9M | -20.4M | -9.2M | -43.9M |
|---|
| 2023 | 2023-12-31 |
4.8M | -49.7M | -60.6M | -22.7M |
|---|
| 2022 | 2022-12-31 |
0 | -29.2M | -25M | -26.4M |
|---|
| 2021 | 2021-12-31 |
0 | -24.8M | -27.1M | -23.7M |
|---|
Every period
Revenue Quarterly
| Period | Ending | Revenue |
|---|
| Q2 '25 | 2025-06-30 | 304K |
|---|
| Q2 '24 | 2024-06-30 | 5.4M |
|---|
| Q2 '23 | 2023-06-30 | 0 |
|---|
Gross Profit Quarterly
| Period | Ending | Gross Profit |
|---|
| Q2 '25 | 2025-06-30 | 232K |
|---|
| Q2 '24 | 2024-06-30 | 4.5M |
|---|
| Q2 '23 | 2023-06-30 | 0 |
|---|
Operating Income Quarterly
| Period | Ending | Operating Income |
|---|
| Q2 '25 | 2025-06-30 | -2.3M |
|---|
| Q2 '24 | 2024-06-30 | -5.8M |
|---|
| Q2 '23 | 2023-06-30 | -9.9M |
|---|
| Q2 '22 | 2022-06-30 | -7.6M |
|---|
| Q2 '21 | 2021-06-30 | -6.5M |
|---|
| Q2 '20 | 2020-06-30 | -5.6M |
|---|
| Q2 '19 | 2019-06-30 | -6.5M |
|---|
| Q2 '18 | 2018-06-30 | -5.7M |
|---|
| Q2 '17 | 2017-06-30 | -5.2M |
|---|
Net Income Quarterly
| Period | Ending | Net Income |
|---|
| Q2 '25 | 2025-06-30 | -3.9M |
|---|
| Q2 '24 | 2024-06-30 | 484K |
|---|
| Q2 '23 | 2023-06-30 | -18.5M |
|---|
| Q2 '22 | 2022-06-30 | -7.4M |
|---|
| Q2 '21 | 2021-06-30 | -6.8M |
|---|
| Q2 '20 | 2020-06-30 | -6.8M |
|---|
| Q2 '19 | 2019-06-30 | -5.5M |
|---|
| Q2 '18 | 2018-06-30 | -4.8M |
|---|
| Q2 '17 | 2017-06-30 | -4.9M |
|---|
Cost of Revenue Quarterly
| Period | Ending | Cost of Revenue |
|---|
| Q2 '25 | 2025-06-30 | 72K |
|---|
| Q2 '24 | 2024-06-30 | 897K |
|---|
| Q2 '23 | 2023-06-30 | 0 |
|---|
Shares Outstanding Quarterly
Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.
| Period | Ending | Shares Outstanding |
|---|
| Q2 '25 | 2025-06-30 | 2.4B |
|---|
| Q2 '24 | 2024-06-30 | 1.2B |
|---|
| Q2 '23 | 2023-06-30 | 923M |
|---|
| Q2 '22 | 2022-06-30 | 715.4M |
|---|
| Q2 '21 | 2021-06-30 | 669.1M |
|---|
| Q2 '20 | 2020-06-30 | 220.3M |
|---|
| Q2 '19 | 2019-06-30 | 145.5M |
|---|
| Q2 '18 | 2018-06-30 | 106.6M |
|---|
| Q2 '17 | 2017-06-30 | 94.5M |
|---|
EPS Annual
The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.
| Period | Ending | EPS |
|---|
| FY25 | 2025-12-31 | 0.00 |
|---|
| FY24 | 2024-12-31 | -0.01 |
|---|
| FY23 | 2023-12-31 | -0.06 |
|---|
| FY22 | 2022-12-31 | -0.03 |
|---|
| FY21 | 2021-12-31 | -0.04 |
|---|